🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The inaugural Common Sense Oncology fellowship in cancer policy 🤩🤩 what a fantastic opportunity to work with global CSO leaders and Bishal Gyawali, MD, PhD, FASCO 🗓️ applications close 15 Oct 2023

In a world first, the UK medicines regulator has approved a therapy that uses CRISPR gene editing as a treatment for diseases go.nature.com/3QDtwuV

Tragic case of fatal #5FU toxicity - grateful that Dr. Anil Kapoor’s family has taken this issue public. CBC News: The National Hopefully will push resources for routine DPYD screening 🇨🇦 ➡️BC Cancer adopted DPYD testing in BC last year🙏 ➡️ we need to learn more about variants in

Productive YOGA committee meeting discussing issues facing 🇦🇺 young oncologists&planning activities for 2024 🙌🏻 Dr Andrew Parsonson in serious business mode 😝 @nicolafoneil Liz Connolly Tim Slattery Mark Nalder Meagan Inglis James McCracken Medical Oncology Group of Australia (MOGA) Melissa Eastgate Dr Deme Karikios

📢 New The Royal Australasian College of Physicians 🧬 Medical Oncology curriculum HAVE YOUR SAY Please review and submit any comments - closes early Jan 🤓 Information sessions - Wednesday 13 Dec 2pm - Monday 18 Dec 2pm ✅ CPD points available racp.edu.au/trainees/advan… Medical Oncology Group of Australia (MOGA) i luv me some chemo jess smith

Register to attend our education session 💻 🙋🏾‍♀️on demystifying being a PI on clinical trials either in person or virtually here: msdmeetingreg.com/event/9456e090… 💉👨🏼‍⚕️A great opportunity to network with other young oncs and learn!

Pleasure to present research in Chicago for #ASCO24. Adding to the evidence for routine DPYD genotype guided dosing as standard of care to reduce treatment toxicity for patients. Great to meet @sony_tuteja and many others also moving research forward in this area.

Neoadjuvant nivolumab plus ipilimumab results in a substantial pathological response in most patients with mismatch repair–deficient colon cancer and appears to be safe. Read the full NICHE-2 phase 2 study results: nej.md/3Ku4X0H

We are looking for a new fellow to come join us at RBWH in 2025 at Queenslands’ largest hospital. Come work at the future home of the new QLD Cancer Centre. As a prior fellow, happy to answer questions. ausyoungoncs Medical Oncology Group of Australia (MOGA) Melissa Eastgate David Wyld smartjobs.qld.gov.au/jobs/QLD-RBH57…

Calling all advanced trainees and young oncologists! The AGITG ASM this year in Brisbane has a great program with a special integrated oncology workshop including how to design your own clinical trial 🤔🔬Registrations: asm.gicancer.org.au Medical Oncology Group of Australia (MOGA) GI Cancer Institute and AGITG Mark Nalder

Registrations for #MOGA24 are open! 👉 moga.org.au/2024-asm the ASM this year in Sydney will feature a fantastic YOGA program: “Precision Medicine for Young Oncologists: What You Need to Know” 🇦🇺 👨‍⚕️👩‍⚕️Medical Oncology Group of Australia (MOGA) ausyoungoncs Omico Australia NECTA

Young Oncologists Group of Australia (YOGA) is running a Transitioning to Consultant Workshop on Sat 30 November! Location: Online 11am - 1pm AEDT More Info/Register: moga.org.au/transitioning-… ausyoungoncs

📣 YOGA will be hosting a transitioning to consultant workshop on Sat Nov 30! A great line up of speakers, topics and suitable for later year trainees & recently fellowed FRACPs 👨‍⚕️👩‍⚕️ More info/register ➡️ moga.org.au/transitioning-… Please note different time zones across states 🇦🇺

👏 Great to see this published! VESTIGE is a negative randomised trial with an important lesson.. ➡️ Give adjuvant FLOT even when there's residual cancer after neoadjuvant chemo. 👀 Looking forward to the translational work annalsofoncology.org/article/S0923-…

🧬Cancer types and genes associated with germline mutations 👇 ASCO OncoAlert JCO Precision Oncology #cancer #oncology #genetics #MedX

🚨 YOUNG ONC WORKSHOP IS HAPPENING THIS MORNING🚨 🙌🏻 Join Zarnie Lwin OAM Mark Nalder Tim Slattery Brandon Lau for great sessions not be missed ⏰ 8am Perth 🕰️ 9am Brisbane ⏰ 10am Sydney & Melb Medical Oncology Group of Australia i luv me some chemo Dr Andrew Parsonson Liz Connolly @nicolafoneil

Nivolumab/ipilimumab versus nivolumab in MSI mCRC (CheckMate 8HW): a randomised, open-label, phase 3 trial 👇Get the full paper in the The Lancet doi.org/10.1016/S0140-… 👉Convincing activity with acceptable toxicity ❗️Practice-changing ESMO - Eur. Oncology

#GI25 this👇🏽is a 🆒 study. FOLFOX-3️⃣B ▪️BOT 🤖 ▪️BAL ▪️BEV #Immunotherapy alone may not work for those with active liver metastases. But in a refractory patient population, this is encouraging to see. Dr. Marwan G. Fakih OncoAlert 💡Need more ideas for patients with liver metastases.

🔥off the press Recent advances in systemic therapy for advanced biliary tract cancer: A systematic review and meta-analysis using reconstructed RCT survival data JHEP Reports doi.org/10.1016/j.jhep… 👉Many trials in 1st line BTC, but not much progress 🤨we need to do better!

1st line encorafenib + cetuximab + mFOLFOX6 vs SOC in BRAF V600E-mCRC 🔎BREAKWATER: PFS + updated OS #ASCO25 👉ORR 65 vs 37 vs 43 % 👉mPFS 12.8 vs 7.1 vs 6.9 mo 👉mOS 30.3 vs 15.1 vs 19.1 mo 👉AE ≥3 76% vs 58 vs 15.7% 🧐 Really effective, new SOC in 1st line ESMO - Eur. Oncology